Drugs / Iguratimod
Trials 23 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03023592 | Feb 2017 → Feb 2018 | Sjogren syndrome | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07057778 | Jul 2025 → Dec 2026 expected | autoimmune thrombocytopenia | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05302024 | Mar 2022 → Dec 2023 | thrombocytopenia due to immune destruction | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05281068 | Sep 2021 → Sep 2023 | autoimmune thrombocytopenia | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04830644 | Mar 2021 → Apr 2022 | Sjogren syndrome | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT02936375 | Sep 2017 → Nov 2020 | lupus nephritis | RenJi Hospital | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06244628 | Jan 2024 → Jun 2027 expected | chronic graft versus host disease | Xuzhou Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT00965757 | Jul 2009 → Sep 2011 | rheumatoid arthritis | Eisai Inc. | Completed | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT06945666 | Aug 2025 → Jan 2027 expected | rheumatoid arthritis | Jie Chang | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04981145 | Jan 2022 → Dec 2024 overdue | Sjogren syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 4 | NCT05626348 | Dec 2021 → Jun 2025 overdue | rheumatoid arthritis | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
| Phase 4 | NCT06146972 | Jun 2021 → Mar 2024 | rheumatoid arthritis | Yanfeng Hou | Unknown | No outcome recorded |
| Phase 4 | NCT04928066 | Mar 2020 → Jun 2023 | rheumatoid arthritis | Qilu Hospital of Shandong University | Completed | No outcome recorded |
| Phase 4 | NCT03368274 | Sep 2017 → Jun 2018 | immunoglobulin G4-related sclerosing disease | Wen Zhang | Unknown | No outcome recorded |
| Phase 4 | NCT03855007 | Jan 2016 → Sep 2023 | rheumatoid arthritis | Qilu Hospital of Shandong University | Completed | No outcome recorded |
| Phase 4 | NCT02275299 | Sep 2013 → Feb 2016 | rheumatoid arthritis | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT01893151 | Jul 2012 → Dec 2015 | rheumatoid arthritis | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT01548001 | May 2012 → Nov 2016 | rheumatoid arthritis | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT01554917 | May 2012 → Aug 2015 | rheumatoid arthritis | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT05789030 | Jul 2022 → Apr 2026 overdue | autoimmune disease | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| — | NCT04515706 | Jan 2021 → Jan 2023 | diffuse cutaneous systemic sclerosis | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT03054545 | May 2017 → May 2018 | lupus nephritis | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT02839941 | Aug 2016 → Jul 2019 | — | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05216757 Comparator | Mar 2022 → Dec 2024 | osteoarthritis, hand | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03660059 Background | Sep 2018 → Apr 2021 | rheumatoid arthritis | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05803135 Comparator | Mar 2023 → Jan 2025 | rheumatoid arthritis | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07115641 Background | Aug 2025 → May 2026 overdue | rheumatoid arthritis | Wangjing Hospital, China Academy of Chinese Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iguratimod | “hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod.” NCT03660059 ↗25“Patients of IgG4-RD with mild symptoms are given one dose of diprospan and Iguratimod, 25mg, Bid.” NCT03368274 ↗ |
| Known as | Careram | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107455 ↗ |
| Known as | IGU | “This multicentre randomised controlled trial aimed to compare the efficacy and safety of iguratimod (IGU) and hydroxychloroquine (HCQ) in patients with active primary Sjögren's...” PMID 41423293 ↗ Dec 20253“Iguratimod (IGU) is a novel conventional synthetic disease-modifying antirheumatic drugs (csDMARD) with good efficacy and safety for the treatment of active RA in China and Japan.” PMID 39056160 ↗ Jul 2024 “Iguratimod (IGU) is a new small molecular, anti-rheumatic drug and has shown the potential for drug repurposing from rheumatoid arthritis (RA) to LN treatment.” PMID 34380536 ↗ Aug 2021 “Iguratimod (IGU) is a new disease-modifying anti-rheumatic drug (DMARD) with a low price” PMID 34327344 ↗ Mar 2021 |
| Known as | Kolbet | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107455 ↗ |
| Known as | T614 | “then take Iguratimod (T614), 25mg, Bid orally for three months.” NCT03368274 ↗ |
| Action | Inhibit | “Macrophage migration inhibitory factor inhibitor” CHEMBL2107455 ↗3“E3 ubiquitin ligase TRAF3IP2 inhibitor” CHEMBL2107455 ↗ “osteoclastogenesis inhibition” NCT05216757 ↗ “Cyclooxygenase-2 inhibitor” CHEMBL2107455 ↗ |
| Modality | Small molecule | “Iguratimod (IGU) is a novel conventional synthetic disease-modifying antirheumatic drugs (csDMARD)” PMID 39056160 ↗ Jul 2024 |
| Route | Oral | “25 mg/tablet, taken orally” NCT01548001 ↗ |
| Target | MIF | “Macrophage migration inhibitory factor inhibitor” CHEMBL2107455 ↗ |
| Target | PTGS2 | “Cyclooxygenase-2 inhibitor” CHEMBL2107455 ↗ |
| Target | TRAF3IP2 | “E3 ubiquitin ligase TRAF3IP2 inhibitor” CHEMBL2107455 ↗ |